$CGON News
Last published 1w ago
- 1w agoCGONCG Oncology, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoCGONCG Oncology Reports Third Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswirePIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk and high-grade Ta NMIBC anticipated November 2026BOND-003 Cohort P and CORE-008 Cohort CX 12-month data
- 1w agoCGONCG Oncology Reports Third Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswirePIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk and high-grade Ta NMIBC anticipated...
- 1mo agoCGONCG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial OfficerGlobeNewswireDALLAS, Oct. 13, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. A highly accomplished biopharmaceutical executive with more
- 1mo agoCGONKuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law FirmPR NewswireNEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. (NASDAQ: CGON) breached their fiduciary duties to
- 1mo agoCGONCGON - 1775835 - CG ONCOLOGY INCEarnings Call TranscriptsHi everyone, my name is Sean Lam and I'm the Head of US Mid-Cap Biotech Equity Research here at Morgan Stanley and welcome to our Global Healthcare Conference. Before we begin, to make you aware of some important disclos
- 1mo agoCGONMorgan Stanley 24th Annual Global Healthcare Conference - CG ONCOLOGY INCEarnings Call TranscriptsHi everyone, my name is Sean Lam and I'm the Head of US Mid-Cap Biotech Equity Research here at Morgan Stanley and welcome to our Global Healthcare Conference. Before we begin, to make you aware of some important disclos
- 2mo agoCGONCG Oncology to Present at Upcoming Investor Conferences in SeptemberGlobeNewswireDALLAS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the
- 2mo agoCGONKuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. (NASDAQ: CGON)...
- 3mo agoCGONCG Oncology Reports Second Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswirePIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected fourth quarter
- 3mo agoCGONCG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet OncologyGlobeNewswireDALLAS, July 27, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today announced the publication of results from the pivotal Phase 3 BOND-003 Cohort C trial evaluating cretostimogene grenadenorepvec
- 4mo agoBNTXSMMTCGONNTHIThe New War on Cancer: Four Public Companies Helping Lead a Medical RevolutionGlobeNewswireDENVER, June 25, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Cancer treatment is undergoing one of the most significant transformations in modern medical history. For decades, physicians relied primarily on
- 5mo agoCGONJEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK - CG ONCOLOGY INCEarnings Call TranscriptsGood morning, everyone. Thank you to those in the room and to those dialed in on the webcast as well. My name is Faisal Khurshid. I'm one of the senior biotech analysts here at Jefferies, and we are here live at the Jeff
- 5mo agoCGONCG Oncology to Present at Upcoming Investor Conferences in JuneGlobeNewswireDALLAS, May 28, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the
- 5mo agoCGONSUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship AwardGlobeNewswirePatrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBCLast year's awardees recently
- 6mo agoCGONCG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive PatientsGlobeNewswire- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat
- 6mo agoCGONCG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBCGlobeNewswire-First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients to be presented- -Visit CG Oncology at booth #3051- DALLAS, May
- 6mo agoCGONCG Oncology Reports First Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswireFollowing alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026 PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in
- 6mo agoCGONCG Oncology to Present at Upcoming Investor Conferences in MayGlobeNewswireDALLAS, May 05, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, will
- 8mo agoCGONCG Oncology Reports 2025 Year End Financial Results and Provides Business UpdatesGlobeNewswirePIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination cretostimogene with
- 8mo agoCGONCG Oncology to Present at the TD Cowen 46th Annual Health Care ConferenceGlobeNewswireIRVINE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer,
- 10mo agoCGONONCYTAKOncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead BiostatisticsGlobeNewswireSAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the appointment of
- 10mo agoONCYCGONZNTLAVBP+1Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026PR NewswireUSANewsGroup.com News Commentary – The oncology landscape is entering a high-velocity regulatory phase as genomics in cancer care expands toward a...
- 10mo agoCGONCG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBCGlobeNewswire- PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial to evaluate an
- 11mo agoCGONSUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship AwardGlobeNewswireTwo applicants will each receive a Grant of $50,000 to support the development of outstanding clinical cancer research to improve the treatment of NMIBCApplications for the fellowship are due on February 27, 2026
- 11mo agoCGONNew Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder CancerGlobeNewswireCretostimogene demonstrated HG-EFS at 3- 6- and 9-months of 95.7%, 84.6% and 80.4%, respectively, in HR BCG UR Ta/T1 Disease in BOND-003 Cohort PCORE-008 Cohort A Data in HR BCG-Naïve NMIBC demonstrates 88% CR and
- 11mo agoCGONCG Oncology Announces New Board Member and Board TransitionGlobeNewswire- Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical
- 11mo agoCGONCG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual MeetingGlobeNewswireIRVINE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing
- 12mo agoCGONCG Oncology Reports Third Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswireInitiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)Demonstrated continued
- 1y agoCGONCG Oncology, Inc. (CGON) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Earnings Call Transcripts
- 1y agoONCYHCMCGONCCCC+1Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape MarketPR NewswireUSA News Group News Commentary – The FDA's unprecedented wave of Breakthrough Therapy Designations through August has accelerated development...
- 1y agoCGONCG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 MonthsGlobeNewswire- Robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG)
- 1y agoCGONCG Oncology Completes Enrollment in PIVOT-006GlobeNewswire– Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) –– One of the largest randomized phase 3 studies in this patient population will encompass broadest range of
- 1y agoCGONCG Oncology's Executive Leadership to Participate in Upcoming Investor ConferencesGlobeNewswireIRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing
- 1y agoCGONCG Oncology Reports Second Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswire- Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting - - Initiated
- 1y agoANIPCGONDelaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI PharmaceuticalsGlobeNewswireIRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing
- 1y agoCLDIREGNCGONMRKPrecision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet NeedsPR NewswireAn estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide...
- 1y agoCLDIREGNVRTXMRK+1Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet NeedsPR NewswireAn estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide...
- 1y agoONCYGALTPRPHCGON+1Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is GoingPR NewswireUSA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report...
- 1y agoCGONCG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferenceGlobeNewswireIRVINE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing
- 1y agoCGONCG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare ConferenceGlobeNewswireIRVINE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing
- 1y agoCGONCG Oncology Reports First Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswire- Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal in Cohort P with
- 1y agoCGONSUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship AwardGlobeNewswire- Award recipients Honored at the American Urological Association's 2025 Annual Meeting - - Fellowship designed to support the development of outstanding clinical cancer research investigators to improve the
- 1y agoCGONCG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual MeetingGlobeNewswire- Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – - 58.3% of patients showed durable complete responses by K-M at 24 months – - 97.3% of all treated patients
- 1y agoCGONCG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025GlobeNewswireIRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing
- 1y agoCGONCG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and UpdatesGlobeNewswire- Durability Results from BOND-003 data will be presented as a late breaker as part of AUA's Practice-changing, Paradigm-shifting Clinical Trials in Urology - - Additional updates from across CG Oncology's clinical
- 1y agoCGONCG Oncology Reports 2024 Year End Financial Results and Provides Business UpdatesGlobeNewswire- Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated CORE-008
- 1y agoCGONCretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and EfficacyGlobeNewswire– Latest BOND-003 data show 75.5% of patients achieved a complete response at any time –– Median duration of response exceeds 28 months and is ongoing –– No close contact precautions needed post cretostimogene treatment
- 1y agoCGONCG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and UpdatesGlobeNewswireIRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing
- 1y agoCGONCG Oncology to Present at the TD Cowen 45th Annual Health Care ConferenceGlobeNewswireIRVINE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing